

Covalon to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, May 6, 2025

MISSISSAUGA, Ontario – April 30, 2025 – (BUSINESS WIRE) – Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced that it will be presenting at the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on Tuesday, May 6, 2025 at 2:30 pm ET in Room 104 B at the Metro Toronto Convention Centre in Toronto. Brent Ashton, CEO of Covalon, will be hosting the presentation and answering questions at the conclusion.

During his presentation, Mr. Ashton will share insights into the company's unwavering mission to prevent complications and save lives in healthcare through innovative, patient-centered technologies. He will also discuss Covalon's strong financial position and highlight the company's key growth drivers.

"We are excited to be part of the Bloom Burton 2025 Healthcare Conference, one of the most respected events in the healthcare investment community," said Ashton. "Covalon's focus on delivering compassionate care solutions that reduce risks and improve patient outcomes has never been more important. Our strong balance sheet, combined with accelerating growth opportunities, positions us well to drive long-term value for patients, providers, and shareholders."

The Bloom Burton Healthcare Investor Conference brings together healthcare companies and investors to connect and collaborate, offering a premier platform for sharing the latest industry developments and investment opportunities.

If you would like to book 1x1 investor meetings with Covalon, and to attend the Bloom Burton & Co. Healthcare Investor Conference, please make sure you are registered here: [REGISTER](#)

Conference Details

Dates: Monday, May 5 – Tuesday, May 6, 2025

Time: 8:30 AM - 5:00 PM ET

Location: Metro Toronto Convention Centre, North Building, 255 Front St W, Toronto, Ontario M5V 2W6

For those who are not able to attend the conference but are interested in learning more about Covalon's solutions, visit www.covalon.com or follow Covalon on [LinkedIn](#), [Facebook](#), [Instagram](#), or [X](#).

To learn more about Covalon, please contact:

Investor Relations, Covalon Technologies Ltd.

Email: investors@covalon.com

Website: <https://covalon.com/>

About Covalon

Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing



healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at www.covalon.com.

About the Conference

The Bloom Burton & Co. Healthcare Investor Conference brings together U.S., Canadian and international investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

About Bloom Burton & Co.

Bloom Burton & Co. is a firm dedicated to accelerating returns in the healthcare sector for both investors and companies. Bloom Burton has an experienced team of medical, scientific, industry and capital markets professionals who perform a deep level of diligence, which combined with our creative and entrepreneurial approach, assists our clients in achieving the right monetization events. Bloom Burton and its affiliates provide capital raising, M&A advisory, equity research, strategic advisory, as well as company creation and incubation services. Bloom Burton Securities Inc. is a member of the Canadian Investment Regulatory Organization (CIRO) and is also a member of the Canadian Investor Protection Fund (CIPF).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend", or variations of such words and phrases or state that certain actions, events, or results "may", "could", "would", "might", "will" or "will be taken", "occur", or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the "Risks and Uncertainties" section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at www.sedarplus.ca, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law.

SOURCE Covalon Technologies Ltd.